1Salomo P, Przewlocka-Kosmala M, Orda A, et al. Plasma levels of brain natfiuretie peptide,, cyclic 3 5 -guanosine monophosphate, endothlirr I and noradrenaline in patients with chronic congestive heart failure. Pol Arch Med Wewn,2003, 109( 1 ) :43-48
2Bettencourt P, Ferreira A, Dias P, et al. Evaluation of brain natriuretic peptide in the diagnosis of heart failure. Cardiology ,2000,93 ( 1-5 ) : 19-25
1Maeda K,Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin - 6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol, 2000;36 (5):1581～1593
2Cargill RI, Barr CS, Coutie WJ, et al. C-type natriuretic peptide levels in corpulmonale and in congestive heart failure. Thorax, 1994;49(12): 1247～1249
3Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B - natriuretic as a rapid,point-of- care test for screening patients udnergoing echocardiography to determine left ventricular dysfunction. Am Heart J ,20011; 141 (3) :367～374
4Kawai K, Hata K,Tokaoka H, et al. Plasma brain natriuretic peptide as a nove therapeutic indicator in idiopathic dilated cardiomyopathy during beta- blocker therapy:a potential of hormone- guided treatment. Am Heart J ,2001; 141 (6) :925 ～932
